Analysis of data from the Multiple Myeloma Research Foundation (MMRF) Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass) study [25] found that CD74 transcript was expressed at detectable levels (transcripts per million [TPM] >1) in CD138+ enriched plasma cells from all 892 newly-diagnosed MM patients included in the study (Figure 4A). The gene discussed is CD74; the disease is plasma cell myeloma.